2026-01-16T08:36:03Z
2026-01-16T08:36:03Z
2025-04-14
2026-01-16T08:36:03Z
In the present work, we analyse stored liver, adipose tissue (perigonadal</p><p>and brown), serum and faecal samples from our previous study and present new</p><p>biochemical, faecal metabolomic and microbiome data.</p><p>We show that oral administration of mirabegron</p><p>significantly increases the expression of uncoupling protein 1 in brown</p><p>adipose tissue and β3-Adrenergic receptor protein in perigonadal white</p><p>adipose and liver tissues. Furthermore, mirabegron treatment changes the</p><p>relative abundance of several genus and families of rat faecal microbiota,</p><p>albeit without restoring the global biodiversity and evenness indexes observed</p><p>in control rats, as well as faecal bile acids composition. These changes are</p><p>probably due to a direct effect of mirabegron on the gut microbiome, rather</p><p>than being mediated by changes in bile acid induced by drug treatment.
Article
Versió publicada
Anglès
Metabolisme; Malalties del fetge; Teixit adipós; Metabolism; Liver diseases; Adipose tissues
Frontiers Media
Reproducció del document publicat a: https://doi.org/10.3389/fphar.2025.1547749
Frontiers in Pharmacology, 2025
https://doi.org/10.3389/fphar.2025.1547749
cc-by (c) Bentanachs, R. et al., 2025
http://creativecommons.org/licenses/by/4.0/